Is NAD+ Safe? Side Effects and Risks in the Research

What Is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells that functions as both an electron carrier in redox reactions and a substrate for enzymatic processes including ADP-ribosylation and adenylation. Two related compounds — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are NAD+ precursors frequently studied as a means of raising intracellular NAD+ concentrations; results from NMN or NR studies cannot be attributed to NAD+ itself. The safety literature on direct NAD+ administration remains sparse, and much of what researchers understand about its physiological role comes from biochemical characterization and precursor-supplementation research rather than controlled human trials of the compound directly.

---

What Is NAD+ Studied For?

Research on NAD+ goes back to 2018 — 8 years — with studies continuing through 2025.

1. Metabolic and Redox Cofactor Function — A 2018 review in Advances in Food and Nutrition Research described how the compound and its phosphorylated form NADP serve as essential cofactors for the majority of cellular redox reactions and are indispensable for maintaining cellular metabolism and respiration.

2. Cellular Senescence and Aging Phenotypes — A 2025 preclinical study published in ACS Nano developed an intracellular recycling strategy targeting senescent cells and reported attenuation of senescence-associated phenotypes in animal models, observing that declining levels of the coenzyme are closely linked to the cellular aging process.

3. Osteoarthritis and Joint Tissue Protection — A separate 2025 preclinical study, also published in ACS Nano, loaded the coenzyme into lubricated hydrogel microspheres and reported that the construct addressed chondrocyte senescence, synovitis, and lubrication loss in an age-related osteoarthritis animal model.

4. NAD+ Biosynthesis Pathway Regulation — A 2022 review in Current Medicinal Chemistry examined small-molecule regulators of NAD+ biosynthetic enzymes and identified maintaining cellular NAD+ homeostasis as a proposed anti-aging strategy, noting the compound's role as a substrate for adenylation and ADP-ribosylation in addition to redox chemistry.

5. Human NAD+ Biosynthesis via Precursor Supplementation — An open-label safety pilot enrolling 3 healthy, middle-aged Japanese men (2024, Endocrine Journal) assessed long-term NMN supplementation — not direct NAD+ administration — and measured downstream effects on NAD+ biosynthesis, metabolism, and sleep; because NMN is a precursor and not the compound itself, these findings inform the broader pathway but cannot be directly attributed to NAD+.

---

How Does NAD+ Work?

The coenzyme operates through two mechanistically distinct roles. As an electron carrier, it cycles between its oxidized (NAD+) and reduced (NADH) forms, shuttling electrons through glycolysis, the citric acid cycle, and oxidative phosphorylation. A 2018 review in Advances in Food and Nutrition Research confirmed this central position in cellular respiration and metabolism.

Beyond redox chemistry, the compound serves as a consumable substrate. Enzymes including sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38 cleave the NAD+ molecule rather than simply cycling it. A 2019 study in Biochimica et Biophysica Acta — Molecular Cell Research characterized CD38, a NAD-glycohydrolase, and showed that it metabolizes NAD+ into the calcium-mobilizing second messengers ADP-ribose, 2'-deoxy-ADPR, and cyclic ADP-ribose using a soluble human CD38 fragment. CD38 activity is relevant to safety discussions because elevated CD38 expression — which increases with age and inflammation — can deplete cellular NAD+ pools significantly. A 2024 observational study in Cells reported that this depletion mechanism complicates exogenous supplementation efforts and identified CD38 inhibition as a potential strategy to improve the pharmacological impact of administered compound.

The 2022 Current Medicinal Chemistry review extended this picture, characterizing small-molecule regulators that target biosynthetic enzymes across the Preiss-Handler pathway, the de novo synthesis route from tryptophan, and the salvage pathway — the three main routes through which cells replenish NAD+.

---

What Does Animal Research Show About NAD+ Safety and Risk?

Preclinical models have generally examined the compound's efficacy in disease contexts rather than its toxicology directly. Two 2025 ACS Nano preclinical studies are instructive.

The first developed hydrogel microspheres loaded with NAD+ for intra-articular injection in an age-related osteoarthritis animal model. The construct addressed three simultaneous disease mechanisms — chondrocyte senescence, synovitis, and lubrication loss — and reported favorable outcomes, though the study was designed to assess therapeutic effect rather than adverse responses specifically.

The second 2025 preclinical study, focused on cellular senescence, engineered a delivery system to overcome what the researchers identified as key barriers to clinical use: the inability of NAD+ to be directly absorbed by intact cells, its chemical instability, and the absence of cell-targeting specificity. These identified barriers are relevant to safety in a practical sense — delivery formulation substantially affects both bioavailability and off-target exposure. Both studies are preclinical; neither provides data applicable directly to human safety assessment.

A 2025 zebrafish developmental model examined NAD+ deficiency rather than excess, finding that biallelic pathogenic variants in NAD+ synthesis pathway genes produce a multi-system congenital condition — congenital NAD deficiency disorder — characterized by cardiac, renal, vertebral, and limb anomalies. This model addresses the consequences of insufficient NAD+ during development, not the safety profile of administered compound, but it reinforces the coenzyme's essential developmental role.

---

What Does Human Research Show About NAD+ Safety?

Direct human safety data on administered NAD+ is very limited in the current study pool. The most relevant human-facing evidence comes from an open-label safety pilot (n=3) published in the Endocrine Journal in 2024 that examined NMN supplementation — an NAD+ precursor — in healthy, middle-aged Japanese men over a long-term period. The study reported on metabolism, sleep, and NAD+ biosynthesis outcomes. Because this trial studied NMN rather than NAD+ itself, its safety findings pertain to precursor administration and cannot be extended to direct NAD+ use.

Two additional human-classified studies in the pool — the 2019 CD38 binding characterization and the 2024 Cells study on skin aging pharmacology — used human-derived cell lines or recombinant human protein rather than enrolled participants. They characterize biochemical behavior and do not report clinical adverse event data.

The 2018 niacin review (nicotinic acid and nicotinamide as NAD+ precursors) notes established clinical use of niacin in metabolic contexts, with flushing being a well-documented effect of nicotinic acid in particular. Again, these are precursor findings and cannot be attributed to NAD+ directly.

The picture the available human research actually supports is narrow: cellular NAD+ homeostasis is measurably disrupted by aging and disease processes; precursor supplementation can influence biosynthetic flux; and direct NAD+ administration faces documented delivery challenges. Formal human safety trials of administered NAD+ — with adverse event reporting, dose-escalation designs, or controlled comparators — are not represented in the current study pool.

---

What Is Still Unknown About NAD+ Safety?

Several gaps stand out from the evidence available.

The delivery problem is unresolved at a human scale. Both 2025 preclinical studies identified membrane impermeability and chemical instability as barriers — observations consistent with why most human-facing research has focused on precursors rather than NAD+ directly. Whether novel delivery systems (such as the hydrogel microspheres or intracellular recycling constructs studied in animals) translate safely to human subjects remains an open question.

CD38's role as a dominant NAD+-consuming enzyme raises a distinct concern: interventions that raise NAD+ levels may simultaneously upregulate CD38, partially offsetting the effect and creating a regulatory feedback loop whose net physiological consequences in humans are not well characterized. The 2024 Cells study flagged this as an active research problem.

The zebrafish developmental model underscores that NAD+ is not biologically inert — its concentration is tightly regulated for a reason, and deficiency during development produces serious structural anomalies. What excess or abnormally distributed NAD+ does in developed human tissue remains understudied.

Finally, the clinical literature on NAD+ precursors (NMN, NR, niacin) is far more developed than the literature on the compound itself. Researchers and readers should apply those findings only to the precursors studied, not to NAD+ directly.

---

Where Can I Buy NAD+?

NAD+ is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---